TNJIF yields 5.08% · JNJ yields 2.13%● Live data
📍 TNJIF pulled ahead of the other in Year 1
Combined, TNJIF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TNJIF + JNJ for your $10,000?
Tianjin Capital Environmental Protection Group Company Limited, together with its subsidiaries, engages in the sewage treatment and construction of the sewage treatment plants in the People's Republic of China. It operates through Sewage Water Processing and Water Plant Facilities Construction; Recycled Water and Pipeline Connection; Heating and Cooling Supply and Related Facilities Construction; Tap Water and Water Plant Facilities Construction; Sale of Environmental Protection Equipment; and All Other segments. The company offers municipal sewage treatment, and water supply and recycling services, as well as sludge treatment, photovoltaic power generation, transformation of achievements in technology research, etc.; and involved in hazardous wastes business. It also provides toll collection services; environment governance, technical consulting services, etc.; technical consulting for water recycling business; energy saving and research, consulting and transfer, and property management services; and industrial solid waste incineration and disposal, and general waste recycling services, as well as invests in construction projects; and manufactures and sells new building materials. The company was founded in 1993 and is based in Tianjin, the People's Republic of China. Tianjin Capital Environmental Protection Group Company Limited is a subsidiary of Tianjin Municipal Investment Company Limited.
Full TNJIF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.